Autopsy report · NCT05581719
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 1 month before it started.
- Ran for about 1 year 5 months before it stopped.
- 14 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Enlivex Therapeutics RDO Ltd.
- Sponsor type
- Industry
- Conditions
- Solid Tumor; Peritoneal Metastases; Peritoneal Cancer
- Interventions
- Allocetra-OTS; Nivolumab; Tislelizumab
- Participants
- 14
- Sites
- 6
- Countries
- Israel, Spain
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.